Compare Thomson Reuters Corp (TRI) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Thomson Reuters Corp vs Zimmer Biomet Holdings Inc — how do they compare? Thomson Reuters Corp trades at $102.42 (market cap $43.89B), while Zimmer Biomet Holdings Inc trades at $89.4 (market cap $16.95B). The key difference: Thomson Reuters Corp is far larger — about 2.6× Zimmer Biomet Holdings Inc's market cap, and Thomson Reuters Corp pays the higher dividend (2.58%). Which is the better fit depends on your goals — on Pluang, investors hold Thomson Reuters Corp for 63 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| TRI | ZBH | |
|---|---|---|
Market Cap | $43.89B | $16.95B |
Volume | 1,648,199 | 2,505,240 |
Sector | Industrials | Health |
52-Week High | $163.45 | $103.98 |
52-Week Low | $76.55 | $79.58 |
Typical Hold Time | 63 Days | 89 Days |
Enterprise Value | $46.51B | $24.02B |
Dividend Yield | 2.58% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Thomson Reuters (TRI) trades at $101.52, up 2.26% today, with bullish technical signals and strong analyst support. The company shows solid fundamentals with 10% organic growth in core businesses and a 21.22% net income margin. Recent strategic moves include divesting its printing unit and launching a proprietary AI model, positioning TRI for tech-focused growth. Cash flow trends show operational strength despite recent negative net cash flow due to strategic investments.
TRI presents a compelling investment case with analyst consensus target of $133.25 (31% upside), supported by recurring revenue growth and AI expansion. Risks include cybersecurity incidents and execution challenges in tech transformation. The stock's current valuation at 26.75 P/E appears reasonable given growth prospects, making it attractive for long-term investors seeking exposure to content and technology services.
Zimmer Biomet (ZBH) trades at $88.49, down 1.33% today, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.07 surpassing the $2.01 estimate. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated to 9.48%. A quarterly dividend of $0.24 was declared, payable in October 2026. Analyst consensus price target is $103.11, implying potential upside from current levels.
The outlook is mixed: solid fundamentals and earnings momentum support long-term value, but technical weakness and elevated debt levels pose near-term risks. Investment appeal hinges on execution of commercial transformation and robotics adoption offsetting competitive pressures. Key risks include margin compression and macroeconomic sensitivity affecting procedure volumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
